Press-release for stocks related to bioscience

Prices are updated after-hours

tags : Bioscience crawled time : 16:00

save search

Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published: 2024-01-09 (Crawled : 16:00) - biospace.com/
SKYE | $12.615 -10.09% 37K

Transportation and Warehousing

| 479.75% | O: -7.02% H: 29.11% C: 15.56%
SNY | News | $46.615 -2.25% 730K

Health Technology

| -8.67% | O: 0.74% H: 0.0% C: 0.0%
obesity disease kidney bioscience clearance trial

Adimab Announces Successful Resolution of Lawsuit Brought Against LinkedUp Bioscience and Tianti Biotherapeutics
Published: 2023-12-21 (Crawled : 16:00) - biospace.com/
SNYNF | News | $94.25 480

Health Technology

| -1.73% | O: -0.1% H: 0.0% C: 0.0%
SNY | News | $46.615 -2.25% 730K

Health Technology

| -3.51% | O: -0.08% H: 0.0% C: 0.0%
bioscience

Skye Bioscience Responds to OTC Markets Promotional Policy
Published: 2023-12-11 (Crawled : 16:00) - biospace.com/
SKYE | $12.615 -10.09% 37K

Transportation and Warehousing

| 300.86% | O: 10.0% H: 15.58% C: 3.9%
bioscience

Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion
Published: 2023-07-13 (Crawled : 16:00) - biospace.com/
SKYE | $12.615 -10.09% 37K

Transportation and Warehousing

| 65768.54% | O: -6.1% H: 6.5% C: 4.5%
sbi-100 review positive bioscience study

Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
Published: 2023-07-06 (Crawled : 16:00) - biospace.com/
SKYE | $12.615 -10.09% 37K

Transportation and Warehousing

| 62814.8% | O: -9.87% H: 19.4% C: 19.4%
glaucoma drug bioscience trial

Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion
Published: 2023-05-15 (Crawled : 16:00) - biospace.com/
SKYE | $12.615 -10.09% 37K

Transportation and Warehousing

| 93433.33% | O: -0.67% H: 16.11% C: 7.38%
sbi-100 review positive bioscience study

Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 As a Potential Treatment for Duchenne Muscular Dystrophy
Published: 2023-03-10 (Crawled : 16:00) - biospace.com/
MSCLF | $0.3407 1.2K

n/a

| Email alert Add to watchlist
sat-3153 treatment preclinical potential duchenne bioscience

Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study
Published: 2023-02-23 (Crawled : 16:00) - biospace.com/
SKYE | $12.615 -10.09% 37K

Transportation and Warehousing

| 47139.06% | O: 1.01% H: 25.67% C: 7.67%
sbi-100 review positive bioscience study ophthalmic emulsion phase 1

Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment
Published: 2023-02-15 (Crawled : 16:00) - biospace.com/
SKYE | $12.615 -10.09% 37K

Transportation and Warehousing

| 35599.75% | O: 1.78% H: 0.0% C: -3.75%
payment bioscience

Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion
Published: 2023-02-02 (Crawled : 16:00) - biospace.com/
SKYE | $12.615 -10.09% 37K

Transportation and Warehousing

| 36821.05% | O: 2.11% H: 36.6% C: 29.64%
sbi-100 pharma services trial bioscience phase 2 ophthalmic emulsion

Satellos Bioscience Announces Development Candidate
Published: 2023-01-03 (Crawled : 16:00) - biospace.com/
MSCLF | $0.3407 1.2K

n/a

| Email alert Add to watchlist
candidate bioscience

Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Published: 2022-12-16 (Crawled : 16:00) - biospace.com/
SKYE | $12.615 -10.09% 37K

Transportation and Warehousing

| 103061.76% | O: -8.09% H: 27.2% C: 8.0%
sbi-100 trial bioscience ophthalmic emulsion phase 1

Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer
Published: 2022-12-13 (Crawled : 16:00) - biospace.com/
SKYE | $12.615 -10.09% 37K

Transportation and Warehousing

| 92813.91% | O: -3.97% H: 12.41% C: 2.76%
bioscience

Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference
Published: 2022-03-08 (Crawled : 16:00) - biospace.com/
REVB | $2.07 16K

| 121.91% | O: -4.59% H: 11.24% C: 3.91%
conference bioscience

Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
Published: 2022-01-06 (Crawled : 16:00) - brightmindsbio.com
DRUG | $1.25 -6.61% 11K

Manufacturing

| -60.63% | O: 0.0% H: 2.22% C: 0.0%
conference bioscience

Harmony Biosciences Publishes Pitolisant Efficacy Data In CNS Drugs
Published: 2021-12-13 (Crawled : 16:00) - biospace.com/
HRMY | $29.05 0.69% 150K

Health Technology

| -26.37% | O: -3.85% H: 0.0% C: 0.0%
drug bioscience

Meridian Bioscience Announces Retirement of CFO Bryan Baldasare
Published: 2021-12-02 (Crawled : 16:00) - biospace.com/
VIVO | $33.97 0.0% 0

Health Technology

| 73.67% | O: -0.41% H: 4.11% C: 1.44%
bioscience

Meridian Bioscience Announces Retirement of Chairman David Phillips
Published: 2021-11-24 (Crawled : 16:00) - biospace.com/
VIVO | $33.97 0.0% 0

Health Technology

| 71.13% | O: -2.12% H: 0.0% C: 0.0%
bioscience

Lynx Biosciences Appoints Sylvaine Cases, Ph.D., as Chief Business Officer
Published: 2021-11-17 (Crawled : 16:00) - biospace.com/
JNJ | News | $148.22 -0.9% 3.3M

Health Technology